The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | HUDSON: Durvalumab combination therapies to overcome PD-L1 blockade resistance in advanced NSCLC
Benjamin Besse, MD, Gustave Roussy Institute, Villejuif, France, discusses the Phase II HUDSON trial (NCT03334617), which compared the use of 4 durvalumab combination therapies to overcome resistance to PD-L1 blockade in previously-treated patients with advanced non-small cell lung cancer (NSCLC). Eligible patients must have been previously treated with anti-PD-L1 immunotherapy and platinum-doublet chemotherapy and had subsequent disease progression. The four combination therapies that were investigated were durvalumab plus either olaparib, danvatirsen, ceralasertib, or oleclumab. The durvalumab plus ceralasertib arm achieved the highest response rate (16.7% compared to less than 5% in the other three arms), the longest progression free survival (6 months compared to less than 3 months in the other three arms), and the longest overall survival (15.9 months compared to a maximum of 11 months in the other three arms). Prof. Besse also discusses how the biomarker-matched cohort in the durvalumab plus ceralasertib arm achieved the highest response rates. The upcoming Phase III LATIFY study (NCT05450692) will further investigate this combination therapy. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
